Financially stable with $469.5 million in cash, Praxis Precision Medicines can fund operations until 2028. Read why my rating on PRAX stock remains as a "Hold".

Praxis Precision Medicines said an independent committee had recommended stopping a late-stage trial of an experimental drug for a movement disorder as it was unlikely to meet the main goal, sending ...

Enhertu improved overall survival versus chemotherapy in HER2-positive metastatic gastric cancer, prompting an interim ...

Praxis Precision Medicines' ulixacaltamide study for essential tremor faces setback as IDMC recommends stopping for futility. Topline results expected in Q3 2025.

Praxis' epilepsy pipeline takes center stage after Ulixacaltamide's Phase 3 futility. Key trials for vormatrigine and ...

The partners are pushing to expand Enhertu’s list of indications beyond its standing uses in breast, lung and gastric cancers ...

Truist lowered the firm’s price target on Praxis Precision (PRAX) to $85 from $175 and keeps a Buy rating on the shares. The firm is removing ...

Needham lowered the firm’s price target on Praxis Precision (PRAX) to $85 from $150 and keeps a Buy rating on the shares. The firm is removing ...

After Study 1’s independent data monitoring committee said the experiment will likely fall short of its primary endpoint with ulixacaltamide in essential tremor, Praxis Precision Medicines Inc. plans ...

AstraZeneca and Daiichi Sankyo's Enhertu has become the first HER2-directed drug to mount a patient survival benefit in a ...

North Carolina legislators appear to be closing in on legislation to provide more funds to help the mountains recover from ...

Praxis Precision Medicines said on Friday an independent committee had recommended that its tremor drug trial be stopped for futility, as the trial was unlikely to meet the main goal. Shares of the ...